Imatinib-resistant CML cell lines or mouse models overexpressing Src-family kinases were shown to respond to the dual BCR–ABL1 – Src-family kinase inhibitor dasatinib, but not nilotinib or Imatinib (147). This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.